CAS 1846570-40-8: 6-Metossi-2-(5-metil-2-furanil)-N-[(1-metil-4-piperidinil)metil]-7-[3-(1-pirrolidinil)propossi]-4-chinolinamina

6-Methoxy-2-(5-methyl-2-furyl)-N-[(1-methyl-4-piperidyl)methyl]-7-(3-pyrrolidin-1-ylpropoxy)quinolin-4-amine is a synthetic quinoline derivative, which is developed through a series of targeted chemical modifications of the quinoline core structure. This compound is engineered to interact selectively with specific receptors within the central nervous system, due to its high affinity for particular receptor subtypes. Its molecular architecture facilitates the modulation of neurotransmitter pathways, by either agonistic or antagonistic activities, depending on its application. In a scientific context, this compound holds significance for its potential application in therapeutic research, primarily focusing on neurological and psychiatric disorders. Its intricate interaction with receptor sites opens pathways to explore treatments for conditions such as depression, anxiety, or neurodegenerative diseases. Furthermore, its structural adaptability allows for further research into selective binding affinities and drug design optimization. The study of this compound may lead to the development of new pharmaceutical agents with improved efficacy and safety profiles, thus offering a promising direction for future neuropharmacological interventions.

CM-579 is a dual inhibitor of G9a and DNMT( IC50:16 nM, 32 nM for G9a and DNMT). It has potent in vitro cellular activity in a wide range of cancer cells.

CM-579